Sharps Provensa™ is the company's premier line of smart safety syringes that offer solutions to global healthcare crises.
Their Ultra-Low Waste™ syringes offer a solution to minimize vaccine waste while offering reliable needlestick protection.
The Sharps Provensa™ needle tip goes through the skin sharp, delivering the medicine or vaccine, and comes out of the body shielded, protecting the healthcare worker and the public.
Sharps Technology syringes are patented and comply with US regulatory and WHO guidelines.
Their safety syringes are currently being produced at the company's ISO certified, FDA-cleared facility for medical device production with CE mark approval.
Grab more key company details here.
And as I mentioned previously, STSS has multiple potential catalysts to know ahead of Thursday's opening bell. Here they are:
No. 1 STSS Potential Catalyst - Another Low Floater Could Provide Significant Potential For Explosive Volatility
According to the Yahoo Finance website, STSS has a low float.
The website reports this profile to have approximately 5.6Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news early in 2023 provide a near term spark?
No. 2 STSS Potential Catalyst - 2023 Could Be A HUGE Year For Sharps (New Product Launch Nears)
Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023
High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond
Company to launch next generation specialty polymer-based syringe products for the healthcare market
NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.
Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors. The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market."
Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment.
Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+Mn units, with additional capacities that can be scaled by 2025 with an additional 100Mn units annually. Products will be manufactured utilizing state-of-the-art Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry.
Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opp. to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the USA that provide specialized solutions for customers that need optionality for their drug filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market."
Read the full article here.
No. 3 STSS Potential Catalyst - With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer
Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products
Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company
Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European customers
NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.
Robert Hayes, Sharps Technology CEO commented: “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them."
"We look forward to a bright future at Sharps Technology," concluded Mr. Hayes. "The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opp. for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023."
Read the full article here.
No. 4 STSS Potential Catalyst - New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter
Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products
Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year
Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.
“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals," commented Robert Hayes, Sharps Technology CEO. "The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”
Read the full article here.
No. 5 STSS Potential Catalyst - Joining The Nasdaq Capital Market In 2022 Opened Sharps To All Kinds Of New Exposure
Sharps Technology, Inc. Announces Closing of $16Mn Initial Public Offering
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of 3.750Mn units at a public offering price of $4.25 per unit. ...
The common st-ock and warrants began trading on The Nasdaq Capital Market on April 14, 2022, under the symbols “STSS” and “STSSW,” respectively.
Read the full article here.
STSS Recap - Multiple Potential Catalysts Could Spark This Nasdaq Idea Near Term
No. 1 - Another Low Floater Could Provide Significant Potential For Explosive Volatility
No. 2 - 2023 Could Be A HUGE Year For Sharps (New Product Launch Nears)
No. 3 - With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer
No. 4 - New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter
No. 5 - Joining The Nasdaq Capital Market In 2022 Opened Sharps To All Kinds Of New Exposure
Coverage is officially initiated on STSS. When time permits, do this: